Statins Reduces the Risk of Dementia in Patients with Late-Onset Depression: A Retrospective Cohort Study

Yang, Ya Hsu; Teng, Hao Wei; Lai, Yen-Ting; Li, Szu Yuan; Lin, Chih Ching; Yang, Albert C.; Chan, Hsiao‐Lung; Hsieh, Yi Hsuan; Lin, Chiao Fan; Hsu, Fu Ying; Liu, Chih Kuang; Liu, Wen Sheng

doi:10.1371/journal.pone.0137914

Cited by 10 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, we have used the NHIRD database to study the association of statin with risk of dementia [15]. We found that statins may reduce the risk of subsequent dementia in patients with LOD [15]. Similarly, Wu et al have also reported the association of statins with reduced risk of dementia in elderly patients [16].…”

Section: Introductionmentioning

confidence: 66%

“…Interestingly, LOD frequently arises in the context of vascular disorders [10][11][12], and it has been proposed complex vulnerability models involving endothelial dysfunction interacting with other complex multidirectional ways to mediate depression [13,14]. Previously, we have used the NHIRD database to study the association of statin with risk of dementia [15]. We found that statins may reduce the risk of subsequent dementia in patients with LOD [15].…”

Section: Introductionmentioning

confidence: 92%

“…Previously, we have used the NHIRD database to study the association of statins with risk of dementia [15]. Current study represents a new analysis from the NHIRD.…”

Section: Data Sourcesmentioning

confidence: 99%

See 2 more Smart Citations

Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study

Yang

Chiu

Teng³

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background. Late onset depression (LOD) often occurs in the context of vascular disease and may be associated with risk of dementia. Aspirin is widely used to reduce the risk of cardiovascular disease and stroke. However, its role in patients with LOD and risk of dementia remains inconclusive. Materials and Methods. A population-based study was conducted using data from National Health Insurance of Taiwan during 1996–2009. Patients fulfil diagnostic criteria for LOD with or without subsequent dementia (incident dementia) and among whom users of aspirin (75 mg daily for at least 6 months) were identified. The time-dependent Cox proportional hazards model was applied for multivariate analyses. Propensity scores with the one-to-one nearest-neighbor matching model were used to select matching patients. Cumulative incidence of incident dementia after diagnosis of LOD was calculated by Kaplan–Meier Method. Results. A total of 6028 (13.4%) and 40,411 (86.6%) patients were defined as, with and without diagnosis of LOD, among whom 2,424 (41.9%) were aspirin users. Patients with LOD had more comorbidities such as cardiovascular diseases, diabetes, and hypertension comparing to those without LOD. Among patients with LOD, aspirin users had lower incidence of subsequent incident dementia than non-users (Hazard Ratio = 0.734, 95% CI 0.641–0.841, p<0.001). After matching aspirin users with non-users by propensity scores-matching method, the cumulative incidence of incident dementia was significantly lower in aspirin users of LOD patients (p=0.022). Conclusions. Aspirin may be associated with a lower risk of incident dementia in patients with LOD. This beneficial effect of aspirin in LOD patients needs validation in prospective clinical trials and our results should be interpreted with caution.

show abstract

Section: Introductionmentioning

confidence: 66%

Section: Introductionmentioning

confidence: 92%

See 1 more Smart Citation

Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study

Yang

Chiu

Teng³

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although studies have shown that statins can reduce the severity of inflammation and improve patient response to ESA, we previously found that response to CERA was not dependent on treatment (such as statin or iron supplement therapy) but on parameters of the clinical response (such as cholesterol and ferritin) to treatment that influenced the erythropoiesis . For this reason, usage of statins or iron supplements was not recorded in this study.…”

Section: Introductionmentioning

confidence: 78%

Fixed dose of long‐acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis

Liu

Chu

Chan

et al. 2016

Clin Exp Pharma Physio

Self Cite

View full text Add to dashboard Cite

Anaemia is an important issue in patients undergoing haemodialysis. We aimed to identify a better dosing schedule of a fixed monthly dose of continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease (CKD) on haemodialysis. The CERA dosing schedule included 100 μg once monthly for 2 months, 50 μg twice monthly for 2 months and then 100 μg once monthly for two months. The effectiveness was determined by comparing haematocrit, nutritional status (serum protein and albumin) and inflammatory markers (tumour necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 and Hepcidin) at the beginning of the study with those at the end of the study. Forty-seven out of 67 patients completed the trial. At the end, haematocrit was significantly higher (34.51 vs 33.22%, P=.004), levels of inflammatory markers were significantly lower (TNF-α (30.71 vs 35.67 ng/mL, P=.007), IL-6 (5.12 vs 7.95 ng/mL, P=.033), hepcidin (60.39 vs 74.39 ng/mL, P=.002)), blood glucose levels were significantly lower (112.40 vs 139.02 mg/dL, P=.003) and albumin was significantly higher (4.11 vs 3.98, P=.001). Patients with a better than average response had a lower initial number of red blood cells (3.3 vs 3.6 × 10(6) /mm(3) , P=.025) and a lower IL-1 (3.8 vs 12.9 ng/mL, P=.01). They also had significantly lower blood glucose levels at the end. (91.3 vs 124.0 mg/dL, P=.03). We demonstrate that a fixed monthly dose of CERA at a twice monthly dosing schedule improves nutrition, reduces the inflammation and corrects anaemia in patients on haemodialysis. This finding may provide a new strategy for treating CKD-related anaemia.

show abstract

“…Seven cohort studies (Chen et al, ; Chuang, Lin, Lin, Sung, & Kao, ; Hendrie et al, ; Hippisley‐Cox & Coupland, ; Li et al, ; C.‐K. Wu et al, ; Yang et al, ) and five case control studies (Booker et al, ; Chen, Liu, Chen, & Wu, ; Corrao et al, ; Horsdal et al, ; Lin et al, ) found that statin use was associated with a reduced risk of dementia. According to these studies, beginning treatment with high doses of lipophilic statins before an early old age (<80 years old) and taking these statins for a long time might reduce the risk of dementia.…”

Section: Resultsmentioning

confidence: 99%

Drug interactions with dementia‐related pathophysiological pathways worsen or prevent dementia

Barus

Béné

Deguil

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

Many risk factors are known to induce or precipitate dementia. Drugs acting via different mechanisms can modulate cognitive performance and exert either beneficial or deleterious effects on cognition through functional or neuropathological mechanisms. This review discusses the association between several classes of drugs and cognitive impairment and dementia risk. These drugs can be divided into drugs targeting CNS disorders (e.g., anticholinergic drugs, antiepileptics, antipsychotics, benzodiazepines, and opioids) and drugs targeting non‐CNS disorders (e.g., antidiabetics, antihypertensives, proton pump inhibitors, and statins). Furthermore, we sought to highlight the pharmacological mechanisms underlying their possible detrimental or beneficial effects on cognition. Anticholinergic and antiepileptic drugs were excluded from this review because their effects on cognition are well known. Studies investigating benzodiazepines have revealed an increased risk of dementia. Conclusions on dementia risk or cognitive impairment regarding opioids and antipsychotic drugs are difficult to draw. These different classes appear to impair cognition not by a single clear mechanism of action specific to each class but by several relatively interdependent and interconnected mechanisms (e.g., impaired neurotransmission, neuroinflammation, neuronal death, oxidative stress, or interactions with dementia‐related pathways). The dementia risk initially associated with the use of proton pump inhibitors might have been overestimated. In contrast, statins, antihypertensive medications, and antidiabetics could potentially decrease the risk of dementia and cognitive impairment by acting in ways opposite to the mechanisms cited above. Linked Articles This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc

show abstract

Statins Reduces the Risk of Dementia in Patients with Late-Onset Depression: A Retrospective Cohort Study

Cited by 10 publications

References 42 publications

Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study

Aspirin and Risk of Dementia in Patients with Late-Onset Depression: A Population-Based Cohort Study

Fixed dose of long‐acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis

Drug interactions with dementia‐related pathophysiological pathways worsen or prevent dementia

Contact Info

Product

Resources

About